Status:
COMPLETED
Cannabinoids and Cerebellar-Motor Functioning
Lead Sponsor:
Yale University
Conditions:
Cannabis
Psychotic Disorders
Eligibility:
All Genders
21-35 years
Phase:
EARLY_PHASE1
Brief Summary
The purpose of this study is to characterize the dose-related effects of delta-9-tetrahydrocannabinol (∆9-THC) in healthy individuals on cerebellum-dependent motor functions.
Detailed Description
The overall aim of the current proposal is to investigate whether acute, IV ∆9-THC administration mediates cerebellar versus forebrain-dependent associative learning in humans as assessed with eyeblin...
Eligibility Criteria
Inclusion
- Must have used cannabis at least once in their lifetime
- No cannabis use in the past month
- Men and women aged 21 to 35 years (extremes included) on the day of the first dosing
Exclusion
- Hearing deficits
- Psychiatric or mental disorders
- Hearing Deficits
Key Trial Info
Start Date :
December 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 7 2015
Estimated Enrollment :
57 Patients enrolled
Trial Details
Trial ID
NCT01853020
Start Date
December 1 2012
End Date
April 7 2015
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VA Connecticut Healthcare System
West Haven, Connecticut, United States, 06516